Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 28; no. 11; pp. 1424 - 1430
• Main Authors: Carrascosa, J.-M., van Doorn, M.B.A., Lahfa, M., Nestle, F.O., Jullien, D., Prinz, J.C.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.11.2014
• Subjects: Biological Products - adverse effects; Biological Products - pharmacokinetics; Biological Products - therapeutic use; Disease Management; Humans; Immunity, Humoral - genetics; Immunity, Humoral - immunology; Immunity, Humoral - physiology; Immunogenetic Phenomena - physiology; Psoriasis - drug therapy; Psoriasis - genetics; Psoriasis - immunology; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.12549

Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision‐making in the management of patients with moderate‐to‐severe psoriasis.